ReviewJournal of diabetes and metabolic disorders2025
Exploring the pathophysiological links between obesity, diabetes, and myocardial dysfunction: an in-depth narrative review.
Review in Journal of diabetes and metabolic disorders, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Multitarget Pharmacological Mechanisms and Safety Profiles of Six Ethnobotanically Prioritized Indonesian Medicinal Plants for Cardiometabolic Disorders: A Systematic Review.Drug design, development and therapy · 2026Pooled it
- Inflammation and Immune Mechanisms in Atherosclerosis.Reviews in cardiovascular medicine · 2026Review
- Association of uric acid-to-HDL cholesterol ratio and coronary atherosclerotic heart disease in patients with and without CKD.BMC cardiovascular disorders · 2026Article
- Gender differences in adiponectin levels among obese individuals and their association with cardiovascular disease.Frontiers in cell and developmental biology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Obesity and type 2 diabetes (T2D) are interconnected metabolic disorders driving the global increase in cardiovascular diseases. Obesity contributes to insulin resistance, systemic inflammation, and metabolic imbalances, which hasten the progression of T2D and impair heart function. Persistent low-grade inflammation, disrupted adipokine signaling, and oxidative stress result in endothelial dysfunction, myocardial fibrosis, and cardiac remodeling. In type 2 diabetes, hyperglycemia worsens these conditions by facilitating the formation of advanced glycation end products (AGEs), mitochondrial dysfunction, and lipid buildup, further disrupting cardiac metabolism and elevating the risk of heart failure. Coronary microvascular dysfunction plays a significant role in myocardial ischemia among individuals with obesity and diabetes. This review explore the complex mechanisms that connect obesity, diabetes, and myocardial dysfunction while emphasizing innovative therapeutic strategies to reduce cardiovascular disease (CVD) risk. Pharmacological treatments, such as SGLT2 inhibitors, GLP-1 receptor agonists, and anti-inflammatory agents, demonstrate potential in enhancing metabolic and cardiovascular health by addressing oxidative stress, inflammation, and glucotoxicity. Meanwhile, lifestyle changes, including weight management and regular physical activity, remain fundamental to both prevention and treatment. Tackling these interconnected pathways is crucial for developing effective solutions to lessen the CVD burden in obese and diabetic populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.